Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent

被引:5
|
作者
van Hoogstraten, Lisa M. C. [1 ,2 ]
Witjes, J. Alfred [3 ]
Meijer, Richard P. [4 ]
Ripping, Theodora M. [1 ]
Kiemeney, Lambertus A. [2 ,3 ]
Aben, Katja K. H. [1 ,2 ]
机构
[1] Netherlands Comprehens Canc Org, POB 1281, NL-6501 BG Utrecht, Netherlands
[2] Radboud Univ Nijmegen Med Ctr, Radboud Inst Hlth Sci, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen Med Ctr, Dept Urol, Nijmegen, Netherlands
[4] Univ Med Ctr Utrecht, Dept Oncol Urol, Utrecht, Netherlands
关键词
muscle-invasive bladder cancer (MIBC); patient and tumour characteristics; survival; treatment; urothelial bladder carcinoma; variation in healthcare; #BladderCancer; #blcsm; LONG-TERM OUTCOMES; RADICAL CYSTECTOMY; MODALITY THERAPY; PRESERVATION; CHEMOTHERAPY; PATTERNS; SCORE;
D O I
10.1111/bju.15697
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non-metastatic muscle-invasive bladder cancer (MIBC), and to compare survival of untreated vs treated patients with similar characteristics. Patients and methods For this cohort study, 15 047 patients diagnosed with cT2-T4aN0/xM0/x urothelial MIBC between 2005 and 2019 were identified in the Netherlands Cancer Registry. Factors associated with remaining untreated were identified using logistic regression analyses. Interhospital variation was assessed using multilevel analysis. Using a propensity score, the median overall survival (mOS) of untreated and treated patients was evaluated. Analyses were stratified by age (<75 vs >= 75 years). Results One-third of patients aged >= 75 years remained untreated; increasing age, worse performance status, worse renal function, cT4a stage and previous radiotherapy in the abdomen/pelvic area increased the odds of remaining untreated. One in 10 patients aged <75 years remained untreated; significant associations were only found for performance status, renal function and cT4a stage. Interhospital variation for remaining untreated was largest for patients aged >= 75 years, ranging from 37% to 69% (case-mix-adjusted). Irrespective of age, mOS was significantly worse for untreated patients: 6.4 months (95% confidence interval [CI] 5.1-7.3) vs 16.0 months (95% CI 13.5-19.1) for treated patients. Conclusion On average, one in five patients with non-metastatic MIBC remained untreated. Untreated patients were generally older and had a more unfavourable prognostic profile. Untreated patients had significantly worse overall survival, regardless of age. Age alone should therefore not affect treatment decision-making. Considering the large interhospital variation, a proportion of untreated patients might be wrongfully denied life-prolonging treatment.
引用
收藏
页码:764 / 775
页数:12
相关论文
共 50 条
  • [41] Muscle-invasive bladder cancer
    Kuebler, H.
    Gschwend, J. E.
    ONKOLOGE, 2012, 18 (11): : 977 - +
  • [42] SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)
    M. Lázaro
    E. Gallardo
    M. Doménech
    Á. Pinto
    A. González del Alba
    J. Puente
    O. Fernández
    A. Font
    N. Lainez
    S. Vázquez
    Clinical and Translational Oncology, 2016, 18 : 1197 - 1205
  • [43] Predictors of Outcome of Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
    Youssef, Ramy F.
    Lotan, Yair
    THESCIENTIFICWORLDJOURNAL, 2011, 11 : 369 - 381
  • [44] EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
    Witjes, J. Alfred
    Comperat, Eva
    Cowan, Nigel C.
    De Santis, Maria
    Gakis, Georgios
    Lebret, Thierry
    Ribal, Maria J.
    Van der Heijden, Antoine G.
    Sherif, Amir
    EUROPEAN UROLOGY, 2014, 65 (04) : 778 - 792
  • [45] Curative Radiotherapy in Elderly Patients With Muscle Invasive Bladder Cancer: The Prognostic Role of Sarcopenia
    Ferini, Gianluca
    Cacciola, Alberto
    Parisi, Silvana
    Lillo, Sara
    Molino, Laura
    Tamburella, Consuelo
    Davi, Valerio
    Napoli, Ilenia
    Platania, Angelo
    Settineri, Nicola
    Iati, Giuseppe
    Pontoriero, Antonio
    Pergolizzi, Stefano
    Santacaterina, Anna
    IN VIVO, 2021, 35 (01): : 571 - 578
  • [46] SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
    A. González del Alba
    G. De Velasco
    N. Lainez
    P. Maroto
    R. Morales-Barrera
    J. Muñoz-Langa
    B. Pérez-Valderrama
    L. Basterretxea
    C. Caballero
    S. Vazquez
    Clinical and Translational Oncology, 2019, 21 : 64 - 74
  • [47] Treatment of muscle-invasive bladder cancer: A systematic review
    Chou, Roger
    Selph, Shelley S.
    Buckley, David I.
    Gustafson, Katie S.
    Griffin, Jessica C.
    Grusing, Sara E.
    Gore, John L.
    CANCER, 2016, 122 (06) : 842 - 851
  • [48] Trimodal therapy for muscle-invasive bladder cancer
    Mathes, Joachim
    Rausch, Steffen
    Todenhoefer, Tilman
    Stenzl, Arnulf
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (12) : 1219 - 1229
  • [49] Perioperative Chemotherapy for Muscle-Invasive Bladder Cancer
    Booth, Christopher M.
    Siemens, D. Robert
    Li, Gavin
    Peng, Yingwei
    Tannock, Ian F.
    Kong, Weidong
    Berman, David M.
    Mackillop, William J.
    CANCER, 2014, 120 (11) : 1630 - 1638
  • [50] Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs
    Guerrero-Ramos, Felix
    Gonzalez-Padilla, Daniel Antonio
    Perez-Cadavid, Santiago
    Garcia-Rojo, Esther
    Tejido-Sanchez, Angel
    Hernandez-Arroyo, Mario
    Gomez-Canizo, Carmen
    Rodriguez-Antolin, Alfredo
    CANCERS, 2024, 16 (19)